| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T685 |
0-211 |
Sentence |
denotes |
There is no currently licensed specific antiviral treatment for MERS- and SARS-CoV infections, and the main focus in clinical settings remains on lessening clinical signs and providing supportive care (183–186). |
| T686 |
212-490 |
Sentence |
denotes |
Effective drugs to manage COVID-19 patients include remdesivir, lopinavir/ritonavir alone or in a blend with interferon beta, convalescent plasma, and monoclonal antibodies (MAbs); however, efficacy and safety issues of these drugs require additional clinical trials (187, 281). |
| T687 |
491-648 |
Sentence |
denotes |
A controlled trial of ritonavir-boosted lopinavir and interferon alpha 2b treatment was performed on COVID-19 hospitalized patients (ChiCTR2000029308) (188). |
| T688 |
649-862 |
Sentence |
denotes |
In addition, the use of hydroxychloroquine and tocilizumab for their potential role in modulating inflammatory responses in the lungs and antiviral effect has been proposed and discussed in many research articles. |
| T689 |
863-945 |
Sentence |
denotes |
Still, no fool-proof clinical trials have been published (194, 196, 197, 261–272). |
| T690 |
946-1110 |
Sentence |
denotes |
Recently, a clinical trial conducted on adult patients suffering from severe COVID-19 revealed no benefit of lopinavir-ritonavir treatment over standard care (273). |
